AbstractIn a prospective study (2009–2011) in healthcare institutions from the Canary Islands (Spain), 6 out of 298 carbapenem non-susceptible Pseudomonas aeruginosa isolates produced a metallo-β-lactamase: four IMP-15, two VIM-2 (including one IMP-15-positive isolate) and one VIM-1. Multilocus sequence typing identified the single VIM-1-producing isolate as clone ST111 and two IMP-15-producing isolates as ST606, but, strikingly, bacterial re-identification revealed that the other three isolates (producing IMP-15 and/or VIM-2) were actually Pseudomonas putida. Further retrospective analysis revealed a very high prevalence (close to 50%) of carbapenem resistance in this environmental species. Hence, we report the simultaneous emergence in ho...
Resistance to carbapenems is emerging, and it is a great problem to therapeutics. Three isolates of ...
Resistance to carbapenems is emerging, and it is a great problem to therapeutics. Three isolates of ...
Carbapenems are therapeutic choice against infections caused by Gram-negative bacilli including stra...
AbstractIn a prospective study (2009–2011) in healthcare institutions from the Canary Islands (Spain...
Carbapenem resistance due to the acquisition of metallo--lactamase (ML)-encoding genes has increased...
Out of 24 nosocomial strains of Pseudomonas aeruginosa from Recife, Brazil, 15 (62%) were metallo-β-...
IMP-13 is a class B metallo-β-lactamase that was first described in a carbapenem-resistant clinical ...
AbstractEighty-six carbapenem non-susceptible Pseudomonas aeruginosa isolates collected in the Natio...
ObjectiveTo study the possible distribution of metallo-β-lactamases among nosocomial Pseudomonas iso...
To characterize a highly divergent IMP-type metallo--lactamase (MBL) variant detected in a multidrug...
To characterize a highly divergent IMP-type metallo--lactamase (MBL) variant detected in a multidrug...
To characterize a highly divergent IMP-type metallo--lactamase (MBL) variant detected in a multidrug...
To characterize a highly divergent IMP-type metallo--lactamase (MBL) variant detected in a multidrug...
To characterize a highly divergent IMP-type metallo--lactamase (MBL) variant detected in a multidrug...
ABSTRACTThirty-four isolates of pan-resistant Pseudomonas aeruginosa producing VIM-2 metallo-β-lacta...
Resistance to carbapenems is emerging, and it is a great problem to therapeutics. Three isolates of ...
Resistance to carbapenems is emerging, and it is a great problem to therapeutics. Three isolates of ...
Carbapenems are therapeutic choice against infections caused by Gram-negative bacilli including stra...
AbstractIn a prospective study (2009–2011) in healthcare institutions from the Canary Islands (Spain...
Carbapenem resistance due to the acquisition of metallo--lactamase (ML)-encoding genes has increased...
Out of 24 nosocomial strains of Pseudomonas aeruginosa from Recife, Brazil, 15 (62%) were metallo-β-...
IMP-13 is a class B metallo-β-lactamase that was first described in a carbapenem-resistant clinical ...
AbstractEighty-six carbapenem non-susceptible Pseudomonas aeruginosa isolates collected in the Natio...
ObjectiveTo study the possible distribution of metallo-β-lactamases among nosocomial Pseudomonas iso...
To characterize a highly divergent IMP-type metallo--lactamase (MBL) variant detected in a multidrug...
To characterize a highly divergent IMP-type metallo--lactamase (MBL) variant detected in a multidrug...
To characterize a highly divergent IMP-type metallo--lactamase (MBL) variant detected in a multidrug...
To characterize a highly divergent IMP-type metallo--lactamase (MBL) variant detected in a multidrug...
To characterize a highly divergent IMP-type metallo--lactamase (MBL) variant detected in a multidrug...
ABSTRACTThirty-four isolates of pan-resistant Pseudomonas aeruginosa producing VIM-2 metallo-β-lacta...
Resistance to carbapenems is emerging, and it is a great problem to therapeutics. Three isolates of ...
Resistance to carbapenems is emerging, and it is a great problem to therapeutics. Three isolates of ...
Carbapenems are therapeutic choice against infections caused by Gram-negative bacilli including stra...